Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597166 | 0.88 | PRKCA (0.47) | PRKCAMMP12NR1I2RXRASCN9A | |
| SCHEMBL3080352 | 0.87 | PRKCA (0.48) | PRKCAMMP12NR1I2RXRASCN9A | |
| SCHEMBL3074886 | 0.85 | PRKCA (0.46) | PRKCAMMP12NR1I2RXRASCN9A | |
| SCHEMBL3087256 | 0.81 | PRKCA (0.48) | PRKCAMMP12NR1I2RXRASCN9A | |
| SCHEMBL3575179 | 0.79 | PRKCA (0.63) | PRKCAMMP12NR1I2RXRASCN9A | |
| SCHEMBL4823223 | 0.79 | NR1I2 (0.47) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL3573742 | 0.78 | PRKCA (0.52) | PRKCAMMP12NR1I2RXRASCN9A | |
| SCHEMBL14253294 | 0.78 | PRKCA (0.48) | PRKCAMMP12NR1I2RXRASCN9A | |
| SCHEMBL895175 | 0.78 | PRKCA (0.57) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL4200779 | 0.78 | PRKCA (0.49) | PRKCAMMP12NR1I2RXRASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232390-B2 | Pentacyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2012-07-31 | — | — | US | disclosed |
| US-20100009959-A1 | Pentacyclic Indole Derivatives as Antiviral Agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009959-A1 | Pentacyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | PRKCA 2745/4885MMP12 3050/4885NR1I2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.